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MicroRNAs (miRNAs) play crucial roles in biological processes involved in diseases. The associations
between diseases and protein-coding genes (PCGs) have been well investigated, andmiRNAs interact
with PCGs to trigger them to be functional. We present a computational method, DimiG, to infer
miRNA-associated diseases using a semi-supervised Graph Convolutional Network model (GCN).
DimiG uses a multi-label framework to integrate PCG-PCG interactions, PCG-miRNA interactions,
PCG-disease associations, and tissue expression profiles. DimiG is trained on disease-PCG associa-
tions and an interaction network using a GCN, which is further used to score associations between dis-
eases andmiRNAs. We evaluate DimiG on a benchmark set from verified disease-miRNA associations.
Our results demonstrate that DimiG outperforms the best unsupervisedmethod and is comparable to
two supervised methods. Three case studies of prostate cancer, lung cancer, and inflammatory bowel
disease further demonstrate the efficacy of DimiG, where top miRNAs predicted by DimiG are sup-
ported by literature.
INTRODUCTION
MicroRNAs (miRNAs) are a type of small non-coding RNAs with a size of about 22 nucleotides, and they
interact with other RNAs to play important roles in transcriptional and post-transcriptional gene regulation
(Bartel, 2004). It is estimated that over 60% of all human protein-coding genes (PCGs) are regulated by
miRNAs (Friedman et al., 2009), and thesemiRNAs have been implicated in diseases. To date, the associations
between diseases and PCGs are well investigated; many disease-PCG associations have been discovered and
collected in public databases, e.g., DISEASES (Pletscher-Frankild et al., 2015), OUGene (Pan and Shen, 2016),
and DisGeNET (Pinero et al., 2017). Compared with PCG’s well-known important roles in diseases, the studies
of effects of miRNAs are increasing. With increasing high-throughput sequencing data generated, more and
more miRNAs are being discovered, and experimentally identifying their functions is costly and time
consuming. Thus, it is imperative to develop computational methods to identify functional miRNAbiomarkers
associated with diseases, especially using rich information buried in disease-associated PCGs.
SomemiRNAs aremainly expressed in certain tissues and show tissue specificity (Ludwig et al., 2016), which
have certain tissue-specific expression patterns associated with diseases (Baker et al., 2017). They are ex-
pected to behave similarly to other disease-associated genes like PCGs or long non-coding RNAs
(lncRNAs). Thus, several existing computational methods have used tissue expression data to infer
gene-disease associations. For instance, GeneTIER makes use of disease-tissue associations to prioritize
disease candidate genes (Antanaviciute et al., 2015). NetWAS identifies disease-associated genes by
combining tissue-specific interaction networks and genome-wide association studies (Greene et al.,
2015). Especially, some methods use tissue expression profiles with machine learning models to infer dis-
ease-associated lncRNAs. For example, DislncRF trains machine learning models on tissue expression pro-
files of disease-associated PCGs and further applies the trained models to infer disease-associated
lncRNAs (Pan et al., 2019). All the above-mentioned studies demonstrated that tissue expression profiles
indeed can facilitate the detection of disease-gene associations.
On the other hand, interaction networks contain rich clues for linking miRNAs to diseases. Many computa-
tional methods have been developed under the context of gene-gene networks (Chen et al., 2019). For
example, Jiang el al. integrate miRNA and disease similarity network and miRNA-disease association to
prioritize disease candidate miRNAs using a network-based approach (Jiang et al., 2010); midp applies
random walk on the interaction network to infer disease-associated miRNAs (Xuan et al., 2015). Similarly,iScience 20, 265–277, October 25, 2019 ª 2019 The Author(s).
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RWRMDA implements random walk on the miRNA functional similarity network to link miRNAs to diseases
(Chen et al., 2012); theMDHGI integrates the predicted association score based on sparse learningmethod
to infer disease-associated miRNAs (Chen et al., 2018c). More closely related studies are as follows:
DRMDA applies stacked autoencoder to learn deep representation for predicting miRNA-disease associ-
ation (Chen et al., 2018a), LRSSLMDA and PBMDA use Laplacian regularized sparse subspace learning and
path-based computational model for miRNA-disease association prediction (Chen and Huang, 2017; You
et al., 2017), BNPMDA uses Bipartite Network Projection based on the known miRNA-disease associations
(Chen et al., 2018b), and KBMF-MDI employs kernelized Bayesian matrix factorization to score miRNA-dis-
ease associations by integrating disease and miRNA similarity (Lan et al., 2018). Similarly, DLRMC infers
disease-associated miRNAs using dual Laplacian regularized matrix completion (Tang et al., 2019).
FamCluRank applies non-negative matrix factorization on the heterogeneous network with node attributes
to predict disease-associated miRNAs (Xuan et al., 2018b). Especially deep learning has been utilized to
extract deep representation for disease-miRNA association prediction (Xuan et al., 2018a).
A common hypothesis for the above methods is they assume that similar miRNAs can be associated with
the same disease and similar diseases would be associated with the same miRNA. Thus, they commonly
train and evaluate the models with representations of miRNAs and diseases as inputs on verified dis-
ease-miRNA associations through cross-validation approach.
However, as pointed out in Lehtinen et al. (2015), in the context of gene function prediction, cross-vali-
dation may be problematic because some gene-function associations are not independent in the bench-
mark set. There exists the same issue for disease-miRNA associations due to the following: (1) miRNAs
from the same family may be associated with the same disease, (2) disease-associated miRNAs from
miRNA-target assay may be derived from the targets that these miRNAs interact with, and (3) the asso-
ciated miRNAs of child diseases are related to the miRNAs of parent diseases in disease ontology. When
training and evaluating the models using cross-validation, randomly dividing the disease-miRNA associ-
ations may cause dependent associations to be separated into the training and test sets, potentially
leading to an overestimated predictive performance. Cross-validating miRNA-disease associations
may not actually reflect the method’s ability to predict new miRNA-disease associations, but rather which
information is dissipated in the benchmark set. In addition, as reported in Park and Marcotte (2012),
there may exist flaws in cross-validation for computational pair-input prediction. One disease or one
miRNA may be associated with multiple miRNAs or diseases, so randomly dividing disease-miRNA pairs
into training and test sets will make some pairs in the test set share either the miRNA or the disease with
the pairs in the training set, which causes the trained models to not generalize well to unseen disease-
miRNA associations.
Thus, during cross-validation, complicated steps are required to make sure that dependent samples are
divided into the same training set or the same test set and that pairs in the training and test sets do not
share the miRNA or disease. It is almost impossible to construct a completely independent test set. An
alternative strategy is that we do not use disease-miRNA associations for model training. For instance,
instead of using miRNA-disease associations, the miRPD approach combines PCG-disease associations
and miRNA-PCG network to score miRNAs and diseases (Mork et al., 2014). This has triggered us to further
investigate disease-miRNA associations based on an interaction network. To date, there exist many high-
confidence disease-PCG associations, and onemiRNAmay share the same disease with its PCG targets; we
will be capable of transferring PCG-associated diseases to miRNAs on an interaction network under a new
semi-supervised framework.
Recently, deep learning has achieved remarkable results in computational biology (Angermueller et al.,
2016; Ching et al., 2018), especially convolutional neural networks (CNNs) (Lecun et al., 1998). CNNs can
capture local correlation buried in data and mainly consist of convolutional layers, pooling layers, and fully
connected layers. Many studies have demonstrated that the CNN networks are powerful in learning the
hidden patterns from complicated biological data. For example, DeepBind (Alipanahi et al., 2015) and
DeepSEA (Zhou and Troyanskaya, 2015) apply CNNs to predict preference of DNA/RNA-binding proteins
and the impact of non-coding variants, respectively. iDeep (Pan and Shen, 2017) and iDeepE (Pan and Shen,
2018) further improve the performance of predicting RNA-binding protein (RBP)-binding sites and motifs
using hybrid CNNs. The iDeepS (Pan et al., 2018) identifies binding sequence and structure preferences of
RBPs simultaneously using CNNs and long short-term memory network.266 iScience 20, 265–277, October 25, 2019
Although the CNN has shown its power, it cannot handle structured datasets, like gene-gene networks. To
analyze these types of network data, graph convolutional networks (GCNs) have been developed (Deffer-
rard et al., 2016; Hamilton et al., 2017; Kipf and Welling, 2017). Under the framework of spectral graph con-
volutions, it encodes both local graph structure and features of nodes. The GCNs have been used on the
graph data to predict polypharmacy side effects, where the graph is a multimodal graph constructed from
protein-protein interactions, drug-protein interactions, and the polypharmacy side effects (Zitnik et al.,
2018). The GCN is a graph-based semi-supervised learning method that does not require labels for all no-
des. This setting is especially powerful for inferring miRNA-associated diseases, becausemanymiRNAs are
not well investigated about their associations with diseases and many disease-PCG associations are avail-
able. Compared with traditional semi-supervised methods (Jia et al., 2016; Wan and Wang, 2019; Zhang
et al., 2018; Zoidi et al., 2018), GCNs can capture the structural information within the node’s local network,
similar to CNNs in images. In addition, one PCG or miRNA can be associated with multiple diseases. Thus,
we can formulate the prediction of disease-miRNA associations as a multi-label classification problem.
In this study, we present a new semi-supervised multi-label learning method, DimiG, based on GCNs to
integrate multiple networks of PCG-PCG interactions, PCG-miRNA interactions, PCG-disease associa-
tions, and tissue expression profiles to infer miRNA-associated diseases. The DimiG does not require
the disease-miRNA associations, and it is trained on the graph consisting of PCG-PCG and miRNA-PCG
interactions, where only PCGs have labeled diseases. Then DimiG is further used to score associations be-
tween diseases and miRNAs.
This study has made the following four major contributions for understanding disease-miRNA associations.
(1) We further demonstrate that cross-validation performance of methods trained on known disease-
miRNA associations could be overestimated and may not be able to reflect the method’s actual ability
to predict new disease-miRNA associations. We have proposed a network-based knowledge transfer
approach for this problem. Considering that an miRNA may share the same disease with its PCG targets
and there exist many high-confidence disease-PCG associations, we will be able to transfer the PCG-asso-
ciated diseases to miRNAs in an interaction network framework. (2) We have formulated disease-miRNA
association prediction as a semi-supervised multi-label node classification in a graph, which can help learn
the complex networks composed of unlabeled miRNAs and labeled PCGs and the multi-label associations.
This is a new prediction protocol for this problem. (3) We use semi-supervised GCN to learn patterns from
PCG-associated diseases on an interaction network, which are further used to score diseases and miRNAs.
This GCN-based approach combines the advantages of deep learning for representation learning and
network-basedmethods. (4) We have further incorporated the domain knowledge into our model construc-
tion. Considering that miRNAs are often expressed in a tissue-specific way, we integrate the expression
profiles across tissues into our GCN framework. Our results demonstrate that informative signals in
more tissues can be captured for aiding the inference of disease-associated miRNAs.
RESULTS
In this study, we first evaluate the prediction performance of DimiG on four tissue expression data with
different number of tissues. Then we compare DimiG with other baseline methods that do not use dis-
ease-miRNA associations for model training on the independent test set, and further compare with
BNPMDA and DRMDA trained using disease-miRNA associations on the unseen disease-miRNA set.
Last, we present three case studies for prostate cancer, lung cancer, and inflammatory bowel disease (IBD).
DimiG Pipeline
DimiG integrates gene network, expression profiles, and PCG-disease associations (Figure S1) using semi-
supervised multi-label GCN. DimiG only requires PCGs with associated diseases (Figure S2) as labels dur-
ing the model training, and then it propagates the node embedding to those miRNAs and further infers
their associated labels. DimiG consists of two layers of GCNs, which require a node feature matrix, an ad-
jacency matrix, and a label matrix. Each node (gene) is represented as a vector of expression profiles across
tissues from GTEx (Lonsdale et al., 2013). The adjacency matrix is derived from the PCG-PCG and PCG-
miRNA interactions. Only PCGs have assigned labels, which are a multi-hot vector corresponding to the
presence of 248 associated diseases. We train GCN models on labeled PCGs and the interaction network,
and the trained GCN model is used to score associations between diseases and unlabeled miRNAs. In the
end, DimiG outputs a 1,0343 248 scorematrix, where 1,034 is the number of miRNAs and 248 is the number
of diseases. More details are shown in Figure 1.iScience 20, 265–277, October 25, 2019 267
..
.
.
.
.
ReLU Sigmoid
1
0
1
.
.
0
Multi-hot encoded disease 
labels for PCGs
1
0
1
.
.
0
0.8
0.2
0.7
.
.
0.9 Predicted disease
labels for miRNAs
0.2
0.9
0.5
.
.
0.1
0.1
0.2
0.6
.
.
0.2
Figure 1. The Flowchart of DimiG with Two-Layer GCN
Each node (gene) is represented as a vector of expression values across tissues with its sum across tissues from GTEx, and the network is constructed from
PCG-PCG and PCG-miRNA interactions. When doing forward propagation, the embedding of the red node in each network is the weighted sum of the
embedding of its neighbors, where all nodes in the network are updated simultaneously. The label is a multi-hot vector indicating the presence of diseases.
In the end, DimiG can infer the probability between diseases and unlabeled miRNAs.The Performance Comparison of DimiG on Four Tissue Expression Datasets
We first checked the impact of the number of epochs on training DimiG. As shown in Figure 2A, the training
and validation loss converge to the same as the number of epochs approaches 50. Thus, in this study, we
use 50 epochs for our below-mentioned experiments. It should be noted that the training loss is larger than
validation loss during the first 30 epochs, which is also observed for the citation network data in the GCN
article (Kipf and Welling, 2017). One possible reason is regularization (e.g., dropout), which is used during
training, but not during validation. Another potential reason is that the features of the genes have certain
discriminative power and they behave similarly to other genes in the training set. After several epochs, the
learned node features are propagated well from interacting neighbor nodes for both training and valida-
tion genes.
Grid search approach is used to select the best parameters for DimiG, where we search the learning rate
with values of [0.001, 0.005, 0.0001, 0.0005], number of neurons in hidden layer with values of [248, 496, 744,
992, 1984], weight_decay with values of [0.001, 0.005, 0.0001] and Dropout with values of [0.5, 0.7, 0.8]. We
yield the best area under receiver operating characteristic (ROC) curve (AUC) when learning rate = 0.0001,
number of neurons = 744, weight_decay = 0.005, and Dropout = 0.8, which are finally used in our DimiG
model.
As shown Figure 2B, DimiG yields the AUCs of 0.748, 0.729, 0.707, and 0.707 on GTEx, E-MTAB-513,
GSE30352, and GSE43520, respectively. It yields the best performance on GTEx, which covers 53 tissues
and thus contains more complete tissues. Compared with GTEx, DimiG achieves a lower performance
on GSE43520. It is presumably because GSE43520 only covers four tissues and many tissues associated
with certain diseases are missing.
When expression profiles from fewer tissues represent node features, DimiG easily suffers from
noises that may be caused by sequencing errors. Of more interest, the area of the ROC curve with
low false-positive rate for GTEx is much bigger than those for other three datasets; this region
is especially important for evaluating predictive models. The results indicate that expression profiles268 iScience 20, 265–277, October 25, 2019
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Figure 2. The Training and Performance of DimiG
(A) The training and validation loss change with the number of epochs on GTEx dataset.
(B) The ROC curve of DimiG using expression profiles from different datasets, where GTEx, E-MTAB-513, GSE30352, and
GSE43520 cover 53, 16, 6, and 4 human tissues, respectively. We train DimiG for each expression dataset separately.across more tissues as node features can improve the prediction performance for disease-miRNA
associations.Comparing DimiG with Other Baseline Methods that Do Not Use Disease-miRNA
Associations for Model Training
In DimiG, tissue expression profiles from GTEx are used as node features. Its variant DimiG-I just uses the
one-hot encoding as the node features. As shown in Figure 3A, the proposed final DimiG yields an AUC of
0.748, which is an increase of 6% over AUC 0.706 of DimiG-I. These results demonstrate that expression
profiles across tissues are very informative for inferring disease-miRNA associations. Another variant
DimiG-C combines the expression profiles and one-hot encoding of nodes as node features and yields
an AUC of 0.728, which is better than DimiG-I, but still worse than DimiG. These results demonstrate
that simply concatenating the expression profile and one-hot encoding of nodes not only introduces
computational burden but also may decrease the prediction performance. One possible reason is that
the one-hot encoding of nodes has no correlations with the expression profiles, making the GCN unable
to encode the node features well.
We also compare DimiG with another published method miRPD, which provides association scores be-
tween diseases and miRNAs derived from three different sources of miRNA-PCG interactions. As shown
in Figure 3A, DimiG outperforms the AUC 0.673 of miRPD-T by 11.1%. Of the three miRPD-basedmethods,
miRPD -T yields the best AUC 0.673, and it is based on the miRNA-PCGs predicted by TargetScan. The
miRPD-C and miRPD-M yield similar AUC, which is much worse than miRPD-T. One potential reason is
that miRPD-C infers association scores only based on a small number of verified miRNA-PCG. miRPD-M
uses a similar number of miRNA-PCG interactions, but it may suffer higher false-positives than TargetScan.
To make a fair comparison, we rerun the miRPD method using the same miRNA-PCG interactions and dis-
ease-PCG associations as DimiG. As shown in Figure 3, miRPD-I-sum and miRPD-I-max yield an AUC of
0.682 and 0.716, respectively, and both are superior to miRPD-T, miRPD-C, and miRPD-M, but they still
perform worse than DimiG.
In addition, our results show that the coexpression-based coding-non-coding co-expression (CNC)
method yields the performance AUC = 0.518, suggesting the co-expressed PCGs with miRNAs are not
enough for identifying high-confidence disease-miRNA associations. It is because CNC is only based on
expression profiles and interaction information of miRNAs is completely ignored.
We also calculate the area under precision-recall curve (AUPRC) of different methods. As shown in Fig-
ure 3B, DimiG yields the best AUPRC of 0.765, which is also better than its two variants DimiG-I and
DimiG-C. In addition, compared with state-of-the-art method miPRD, the miRBD-T yields an AUPRC of
0.708, which is 9% worse than the AUPRC 0.765 of DimiG. However, miRPD-I-sum and miRPD-I-max yield
much lower AUPRCs than other methods.iScience 20, 265–277, October 25, 2019 269
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Figure 3. The Performance of DimiG Using Expression Profiles as Node Features from GTEx and Baseline Methods
(A) ROC curve.
(B) Precision-recall curve. AUC is the area under ROC curve, and AUPRC is the area under precision-recall curve.All the above results show that DimiG is are able to achieve better performance for inferring disease-
miRNA associations, which is not a surprise because GCNs can better integrate interaction network data
and tissue expression profiles, can operate on graphs similarly to CNNs on images, and can take the fea-
tures and connectivity of nearby nodes into account.Performance Comparison of DimiG on the Unseen Disease-miRNA Set
We also compare DimiG with other two state-of-the-art supervised methods BNPMDA and DRMDA on the
unseen disease-miRNA set; both BNPMDA and DRMDA use disease-miRNA associations for model
training. As shown in Figure 4, on this unseen disease-miRNA set, DimiG yields an AUC of 0.710 and an
AUPRC of 0.724, which are better than the performance of BNPMDA with an AUC of 0.686 and an AUPRC
of 0.698 and the performance of DRMDA with an AUC of 0.708 and an AUC of 0.715. The results indicate
that DimiG outperforms the state-of-the-art supervised methods on inferring new disease-miRNA associ-
ations. The AUC 0.687 of BNPMDA on this unseen disease-miRNA set is lower than the reported 5-fold
cross-validation AUC of 0.898. Similarly, the AUC 0.708 of DRMDA is also lower than the reported 5-fold
cross-validation AUC of 0.916. It should be noted that there still exist some possible dependent dis-
ease-miRNA pairs with the training set derived fromHMDD v2.0. The results demonstrate that the methods
trained on disease-miRNA associations may yield biased cross-validation performance, which could not
reflect the methods’ actual ability to predict unseen miRNA-disease associations and generalize well to
new miRNA-disease associations, as observed in Park and Marcotte (2012). As DimiG does not use any dis-
ease-miRNA associations, the performance of DimiG (an AUC of 0.710) on this unseen disease-miRNA set is
consistent with the performance (an AUC of 0.748) on the full independent test set constructed fromHMDD
v3.0. The results indicate that the reported performance reflects DimiG’s ability to infer new disease-miRNA
associations.Case Studies
We present three case studies of miRNAs associated with prostate cancer, lung cancer, and IBD to demon-
strate the applicability of DimiG for inferring disease-associatedmiRNAs. The top predicted candidates for
these three diseases are checked with verified associations from literature and public databases, HMDD
v3.0 and dbDEMC v2.0. In addition, we evaluate the disease-specific prediction performance of DimiG.
Prostate Cancer
We first investigate the prediction of prostate cancer-associated miRNAs from DimiG. Of the 1,034
miRNAs, top 30 miRNA candidates predicted by DimiG are given in Table 1. Eighteen miRNAs are sup-
ported by the literature or database dbDEMC v2.0 and five miRNAs are used as biomarker for detecting
prostate cancer. For example, a meta-analysis shows that the first miRNA miR-939 and the eighth miRNA
miR-661 are downregulated and the ninth miRNA miR-637 is upregulated in recurrent prostate cancer (Pa-
shaei et al., 2017). This study also finds that prostate cancer-associated CTNNB1 (Anastas and Moon, 2013)270 iScience 20, 265–277, October 25, 2019
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Figure 4. The Performance of DimiG, BNPMDA, and DRMDA on the Unseen Disease-miRNA Dataset
Here, DimiG uses expression profiles as node features from GTEx; BNPMDA and DRMDA are trained on known disease-
miRNA associations.
(A) ROC curve.
(B) Precision-recall curve.is one hub gene for its interacting targets in a gene network. That is to say, the predicted miRNA genes by
DimiG in Table 1 are well consistent with existing knowledge.
In another study, the second miRNA miR-93 is frequently overexpressed in prostate cancer and downregu-
lates capicua levels (Choi et al., 2015). In dbDEMC v2.0, three miRNAs miR-874, miR-766, and miR-625 are
differentially expressed in prostate cancer. Of them, miR-625 and miR-874 share the same gene target
HMGA1 in prediction channel of RAIN database withmiR-765. The remaining threemiRNAs in the top 10 can-
didates either regulate prostate cancer-associated genes or activate prostate cancer-associated pathway.We
have also noted that of the top 10 miRNAs, only miR-92a and miR-765 are recorded in HMDD v3.0, and the
others are not. These results indicate that DimiG can infer novel disease-miRNA associations currently not
in the curated databases. Of the remaining 20 miRNAs, eight miRNAs are supported to be associated with
prostate cancer by literature and five miRNAs are used as biomarkers for detecting prostate cancer in a filed
patent. The results indicate that DimiG is powerful in identifying disease-associated miRNAs.
As shown in Figure 5A, of the 176 prostate cancer-associated miRNAs in HMDD v3.0, 21 are in the top 50
predicted candidates by DimiG. Six of the 15 prostate cancer-associated miRNAs in dbDEMC v2.0 belong
to the top 50 candidates predicted by DimiG (Figure S3A). On the prostate cancer-specific dataset con-
structed from HMDD v3.0, DimiG yields an AUC of 0.724, 0.697, 0.675, and 0.664 on GTEx, E-MTAB-513,
GSE30352, and GSE43520, respectively (Figure 5B). Similarly, on the dataset constructed from dbDEMC
v2.0, DimiG achieves an AUC of 0.844, 0.836, 0.729, and 0.684 on GTEx, E-MTAB-513, GSE30352, and
GSE43520 for prostate cancer, respectively (Figure S3B). The performance is better than that on the dataset
constructed from HMDD v3.0 because the extracted disease-miRNA associations are experimentally veri-
fied using low-throughput methods and are more reliable. We can observe that more tissues can provide
informative clues for predicting prostate cancer-associated miRNAs; even some tissues may be considered
not relevant to prostate cancer. The results further demonstrate the power of DimiG.
We further investigate the predicted miRNA candidates using verified prostate cancer-associated miRNAs
from miRCancer and PhenomiR. Of the top 50 predicted miRNAs by DimiG, 10 miRNAs are supported by
miRCancer (Figure S4A) and 16 miRNAs are supported by PhenomiR (Figure S5A). On the prostate cancer-
specific set derived from miRCancer, as shown in Figure S4B, DimiG yields an AUC of 0.755, 0.743, 0.690,
and 0.695 using GTEx, E-MTAB-513, GSE30352, and GSE43520, respectively. As demonstrated in Fig-
ure S5B, for the prostate cancer-specific set collected from PhenomiR, DimiG achieves an AUC of 0.723,
0.713, 0.645, and 0.653 using GTEx, E-MTAB-513, GSE30352, and GSE43520, respectively. DimiG achieves
similar results on the two databases as HMDD v3.0.
Lung Cancer
We investigate the prediction ability of DimiG for lung cancer-associated miRNAs. There are 172 such
miRNAs recorded in the HMDD v3.0 for lung cancer. As shown in Figure 5C, of the 172 miRNAs, 12 miRNAsiScience 20, 265–277, October 25, 2019 271
Rank MiRNA Name Reason Support Evidence
1 miR-939 Downregulated PMID:28651018
2 miR-93 Overexpressed in prostate cancer, and downregulates
capicua levels to promote prostate cancer progression
PMID:26124181
3 miR-92a Regulates tumor suppressor PTEN PMID:24098737
4 miR-874 Upregulated dbDEMC v2.0
5 miR-766 Downregulated dbDEMC v2.0
6 miR-765 Mimics the expression of oncogenic HMGA1 in prostate
cancer
PMID:24837491
7 miR-744 Promotes prostate cancer progression by activating Wnt/
b-catenin pathway
PMID:28107193
8 miR-661 Downregulated PMID:28651018
9 miR-637 Upregulated PMID:28651018
10 miR-625 Upregulated dbDEMC v2.0
11 miR-608 Target overexpressed FLOT1 in prostate cancer PMID:28549468
12 miR-5196 – –
13 miR-5193 Downregulates TRIM11 in prostate cancer PMID:30608062
14 miR-504 Represses overexpressed FOXP1 in prostate cancer PMID:23022474
15 miR-5011 – –
16 miR-491 Interact with PDGFRA to reduce prostate cancer cell
migration
PMID:29312807
17 miR-486 A prostate cancer driver PMID:29069829
18 miR-4739 Biomarker for prostate cancer Patent: WO2015190584A1
19 miR-4731 – –
20 miR-4728 Target MST4 involved in prostate cancer progression PMID:25950472
21 miR-4726 Biomarker for prostate cancer Patent: WO2015190584A1
22 miR-4725 Biomarker for prostate cancer Patent: WO2015190584A1
23 miR-4723 Regulate Abl kinases in prostate cancer PMID:24223753
24 miR-4716 – –
25 miR-4667 Biomarker for prostate cancer Patent: WO2015190584A1
26 miR-4644 – –
27 miR-455 Target eIF4E as tumor suppressor in prostate cancer PMID:28350134
28 miR-4505 Biomarker for prostate cancer Patent: WO2015190584A1
29 miR-4498 – –
30 miR-4447 – –
Table 1. The Top 30 Candidate Prostate Cancer-Related miRNAs Predicted by DimiG and Their Support Evidences
in Literature
– Means no support evidence.
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Figure 5. Venn Diagram and ROC Curve for Predicting Associated miRNAs for Prostate Cancer, Lung Cancer, and
IBD Using DimiG
(A) The overlap between the top 50 predicted miRNAs by DimiG and prostate cancer-associated miRNAs in HMDD v3.0.
(B) ROC curve for predicting prostate cancer associated miRNAs using four tissue expression datasets.
(C) and (D) (C) Venn diagram and (D) ROC for lung cancer.
(E) and (F) (E) Venn diagram and (F) ROC for inflammatory bowel disease (IBD)are in the top 50 lung cancer-associatedmiRNAs predicted by DimiG. Then we evaluate the prediction per-
formance on the dataset consisting of 172 lung cancer-associated miRNAs and 172 miRNAs not associated
with lung cancer in HMDD v3.0. As shown in Figure 5D, DimiG yields an AUC of 0.733, 0.701, 0.649, and
0.674 for GTEx, E-MTAB-513, GSE30352, and GSE43520, respectively.
We further report the prediction ability on another lung cancer-specific dataset derived from dbDEMC
v2.0. In this dataset, there are 16 miRNAs associated with lung cancer and another 16 miRNAs notiScience 20, 265–277, October 25, 2019 273
associated with lung cancer. Of the 16 miRNAs associated with lung cancer, one is in the top 50 predicted
miRNAs by DimiG (Figure S3C). As shown in Figure S3D, DimiG achieves an AUC of 0.925, 0.808, 0.806, and
0.869 for GTEx, E-MTAB-513, GSE30352, and GSE43520, respectively. The results also indicate that infor-
mative clues can be captured in more tissues for predicting lung cancer-associated miRNAs.
According to miRCancer database, 60 miRNAs are associated with lung cancer. Of the 60 miRNAs, three
are in the top 50 miRNAs predicted by DimiG (Figure S4C). On the lung cancer-specific set derived from
miRCancer (Figure S4D), DimiG yields an AUC of 0.778, 0.740, 0.775, and 0.705 using GTEx,
E-MTAB-513, GSE30352, and GSE43520, respectively. Based on PhenomiR, 190 miRNAs are associated
with lung cancer. Of them, 10 miRNAs are in the top 50 candidates predicted by DimiG (Figure S5C). In
addition, as shown in Figure S5D, DimiG obtains an AUC of 0.781, 0.751, 0.757, and 0.754 using the four
expression datasets GTEx, E-MTAB-513, GSE30352, and GSE43520, respectively. All the above results
show that DimiG achieves promising performance for lung cancer.
Inflammatory Bowel Disease
Beside cancer, we also investigate DimiG’s prediction ability for another non-cancer disease IBD. In this
study, we predicted associated diseases for 1,034 miRNAs, of which 18 miRNAs are deposited for IBD.
Seven of the 18 miRNAs are in the top 50 miRNAs predicted by DimiG (Figure 5E). As shown in Figure 5F,
DimiG yields an AUC of 0.799, 0.758, 0.756, and 0.673 for GTEx, E-MTAB-513, GSE30352, and GSE43520,
respectively. The results show that we can use DimiG for other non-cancer diseases.
DISCUSSION
In this study, we present a semi-supervised multi-label GCN framework to integrate heterogeneous net-
works of tissue expression profiles, miRNA-PCG interactions, PCG-PCG interactions, and disease-PCG
interaction to infer disease-associated miRNAs. The whole pipeline is under the context of interaction
network, where disease-miRNA associations are completely not involved in model training. CNN cannot
directly process the non-Euclidean domain data, like network data. However, GCN can handle these types
of data; they are specially designed to extract abstract features from network data. To prove that, we use
T-distributed Stochastic Neighbor Embedding (T-SNE) to map the learned node features in the last hidden
layer by the GCN and the original node features from expression profiles in GTEx to 2D space. As shown in
Figure S6, the learned node features by GCN have a better shape than original node features. We demon-
strate that cross-validating the methods trained on disease-miRNA associations yields an overestimated
performance. Our results demonstrate that DimiG outperforms other state-of-the-art methods, which
do not require disease-miRNA association information, and two methods trained on disease-miRNA
associations.
In this study, we need to set several cutoff values (Figure S1) for PCG-PCG interactions from STRING data-
base, PCG-miRNA interactions from RAIN database, and disease-PCG associations from DISEASES data-
base. All the three databases are developed by the same group, they use similar data quality control, and
the confidence values are all scored using the similar pipeline from multiple channels, including experi-
ments, knowledge, text mining, and prediction. Thus the constructed graph should follow GCN’s assump-
tion that it is a simple one-modal graph, in which all nodes are of the same type (all nodes are genes) and all
edges have the same semantic meaning (Kipf and Welling, 2017).
As shown in Figure S7, for the low cutoff values of STRING with 300 and RAIN with 0.10, DimiG yields much
lower performance with AUC 0.653, it is because lower cutoff may introduce more false-positive interactions.
For cutoff value of STRING greater than 400 and cutoff value of RAIN greater than 0.15, DimiG yields similar
AUCs. DimiG yields the best AUC 0.754 at cutoff values 400 and 0.20 for STRING and RAIN, respectively, but
these higher cutoff values will lead to fewermiRNAs. Thus, we use cutoff value 400 of STRINGand 0.15 of RAIN
in this study, and DimiG yields an AUC 0f 0.748 and is capable of finding more miRNAs, which is just a little
lower than 0.753 with cutoff value 400 and 0.20 for STRING and RAIN databases, respectively, as the trade-off.
We also evaluate the impact of confidence thresholds 1.5 and 2.5 for disease-PCG associations on the perfor-
mance of DimiG. As shown in Figure S8, DimiG yields an AUC of 0.719 and 0.742 for thresholds 1.5 and 2.5,
respectively; both are lower than 0.748 when using threshold 2. The possible reason is that lower confidence
threshold 1.5 introduces more false-positives for model training and higher threshold 2.5 makes the number
of training samples much fewer, which are both not good for training machine learning model. In this study,
we use PCG-PCG interactions from STRING v10 instead of STRING v11, because both RAIN and DISEASES274 iScience 20, 265–277, October 25, 2019
databases are based on STRING v10. Some gene identifiers are changed between STRING v10 and v11. We
directly use PCG-PCG interactions from STRING v11 for DimiG, only 5,092 PCGs are kept for constructing the
interaction network, and DimiG achieves a lower AUC of 0.718.
There are other computational models with reported cross-validation AUC over 0.8, in which disease-
miRNA associations are involved in model training. We demonstrate that cross-validation could report
overoptimistic performance of the methods and could not generalize well to unseen disease-miRNA asso-
ciations. Disease-miRNA associations can be incorporated into model training; however, randomly
dividing the disease-miRNA pairs into the training and test sets for cross-validation could be biased. To
better evaluate the performance of one model, a strictly independent test set should be at least con-
structed; e.g., the model is trained on all data published up to a specific year and predictions are evaluated
on data published after that, or the model is trained on data in the older version of database and evaluated
on those new added disease-miRNA associations in the updated database. In addition, DimiG predicts
associated miRNAs for 248 diseases in one model. Many previous methods formulate the disease-miRNA
prediction as binary classification problems, and they require constructing negative disease-miRNA asso-
ciations, which may introduce false-negatives into model training.Limitation of the Study
In this study, we used only expression profiles across tissues as node features. Some studies have revealed
that functional domain information can assist identifying disease-associated miRNAs (Yang et al., 2018). In
future work, we can combine the gene ontology (GO) information and expression values across tissues into
the node features, or ensemble the two GCNmodels trained on each representation, which is expected to
further improve the prediction performance of DimiG.
DimiG does not require disease-miRNA associations for model training, but it requires the miRNA-PCG in-
teractions to construct the graph. Each miRNAmust have at least one interacting PCG; all nodes, including
miRNAs and PCGs, need be present during the training. Thus the trained node embedding can be prop-
agated tomiRNAs and further used for inferringmiRNA-associated diseases. This preconditionmakes us to
discard some miRNAs, and DimiG cannot infer associated diseases for these miRNAs without interacting
PCGs. In addition, more and more novel miRNAs are being discovered, and their interactions with PCGs
may not be readily available. Thus the trained models cannot be generalized to miRNAs not in the graph.
Luckily, some recent GCN models have tried to solve this issue, which are trained on a set of nodes and
generalized to any augmentation of the graph (Hamilton et al., 2017). This inductive GCN model can be
applied for novel miRNAs not in the graph in our future study.Conclusion
In this study, we present a semi-supervisedmulti-label learning framework DimiG to integrate interaction data
for inferring miRNA-associated diseases. DimiG does not use any disease-miRNA associations for model
training. This new approach achieves promising performance and outperforms other baseline methods not
trained on disease-miRNA associations with a large margin on our benchmark dataset. We observe that
cross-validation performance of methods trained on known disease-miRNA associations could be overesti-
mated and could not reflect their actual abilities for inferring new disease-miRNA associations. Our results
demonstrate that the tissue expression profiles can provide informative signals for inferring disease-miRNA
associations. We expect DimiG to be used to discover novel miRNA biomarkers for diseases and that the
framework can be extended to other tasks based on network data, e.g., functional annotations of proteins.METHODS
All methods can be found in the accompanying Transparent Methods supplemental file.DATA AND CODE AVAILABILITY
All the data and code are available at https://github.com/xypan1232/DimiG or http://www.csbio.sjtu.edu.
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Transparent Methods 
We collect genome-wide tissue expression profiles from RNA-seq data, disease-associated PCGs, PCG-
PCG interactions, miRNA-PCG interactions. These data are fed into a semi-supervised multi-label GCN 
using PCGs as training and validating. Then the trained GCN model is propagated into miRNAs to score 
their associations with diseases. 
1 Data sources 
One recent benchmark study (Huang et al., 2018) shows that among 21 widely used protein-protein 
interaction databases, STRING (Szklarczyk et al., 2015)is one of the three databases having the best 
performance for discovery of disease genes. Like the STRING database, miRNA-gene interaction 
database RAIN(Junge et al., 2017) and disease-gene association database DISEASES(Pletscher-Frankild 
et al., 2015) also integrate different sources of data, including text mining, knowledge, experiments and 
predictions using similar techniques and scoring schema, and they are developed by the same group and 
use the same gene identifiers. For disease-miRNA associations, the widely used HMDD database(Li et al., 
2014) is used as the benchmark set for evaluating disease-miRNA association prediction. 
1.1 Tissue expression data 
We download the GTEx tissue expression data (GTEx_Analysis_v6p_RNA-seq_RNA-SeQCv1.1.8) 
across 53 tissues (Lonsdale et al., 2013). It contains 19,732 PCGs and 2,833 miRNA genes. Of the 2,833 
miRNAs, only 1,244 miRNAs are in miRBase v20 (Kozomara and Griffiths-Jones, 2011). As a 
comparison, we also collected three raw RNA-seq datasets, E-MTAB-513 across 16 tissues (Derrien et al., 
2012), GSE43520 across four tissues (Necsulea et al., 2014) and GSE30352 across six tissues (Brawand 
et al., 2011). The raw reads are mapped to the same reference genome as GTEx using STAR version 
2.5.0b (Dobin et al., 2013) and quantified using Cufflinks (Trapnell et al., 2014). For a tissue with 
multiple samples, we calculate the median expression values for this tissue. The expression values are 
log-transformed using logଶሺ1 ൅ ݔሻ , which is further normalized across tissues by the fraction of 
expression of one gene in one tissue relative to the sum of its expression in all tissues. In addition, we add 
another feature of the sum of one gene’s expression across all tissues. 
1.2 Disease-PCG associations 
We download the integrated disease-PCG associations from DISEASES database (Pletscher-Frankild et 
al., 2015). DISEASES database has multiple channel of evidences, e.g. knowledge, experiments and text 
mining, to support the associations. Each disease-PCG association is assigned a confidence score. In this 
study, we only use associations with confidence scores greater or equal to 2. All gene names are mapped 
to Ensembl gene identifiers and diseases are represented in Disease Ontology ID (Schriml et al., 2012). In 
total, we obtain 86,430 associations between 4,161 diseases and 9,636 PCGs. Figure S2A shows the 
disease label distribution for PCGs. 
1.3 Disease-miRNA associations 
We extract the disease-miRNA associations from database HMDD v3.0 (Li et al., 2014), which has 
32,281 associations between 1,102 miRNA genes and 850 diseases. After removing some associations 
whose disease name have no DOID, we build a set with 24,320 unique disease-miRNA associations 
between 1,007 miRNAs and 582 diseases. We further map the miRNA names into Ensembl gene 
identifiers. In the end, we obtain 6,829 associations between 548 miRNAs and 486 diseases. Figure S2B 
illustrates the disease label distribution for miRNAs. 
1.4 PCG-PCG interactions 
The human gene-gene interactions are extracted from widely used database STRING v10 (Szklarczyk et 
al., 2015), which houses millions of gene-gene interactions across multiple species. In STRING, each 
interaction is scored according to multiple evidences, including experiments, knowledge, prediction and 
text mining. The higher the score is, the more reliable this interaction is. We mapped all gene names to 
Ensembl gene ID and only select those interactions with confidence score greater than 400 (confidence 
values are between 1 and 1000), which is the medium confidence score in STRING database. In total, we 
obtain 1,481,757 interaction pairs of 18,883 PCGs. 
1.5 miRNA-PCG interactions 
We extract the human miRNA-PCG interactions from RAIN database (Junge et al., 2017), which 
integrates miRNA-gene interactions from text mining, experiments, knowledge and predictions. In total, 
RAIN scores 46,472 human miRNA-gene interactions according to different evidences. In this study, we 
only select those interactions with combined score greater than 0.15, which is used as default cut-off in 
the webserver. We mapped all miRNA names to Ensembl gene ID. In total, we obtained 173,662 
interaction pairs between 17,686 PCGs and 1,725 miRNAs. 
2 Data processing 
We integrate the above tissue expression profiles, PCG-PCG interactions, miRNA-PCG interactions and 
PCG-disease associations to score diseases and miRNAs. When constructing the DimiG, we process the 
data as the following: 1) when constructing a graph, each PCG has at least one interacting PCG and each 
miRNA has at least one interacting PCG; 2) both the PCGs and miRNAs in the graph have expression 
profiles across tissues as node features; 3) the PCGs in the graph should be associated with at least one 
disease, since diseases are the labels of PCG nodes and they are used to calculate the training loss for 
model training. The whole processing is shown in Figure S1. Finally, we obtained 7,222 genes with 6,188 
PCGs and 1,034 miRNAs, and 248 diseases as the labels. 
Here, we use the experimentally verified miRNA-disease associations to evaluate the performance of 
DimiG. After removing those associations whose disease is not among the 248 diseases, we obtain 2,695 
associations for 91 diseases. As negative control examples, for each disease, we randomly select the same 
number of miRNAs not associated with the disease in HMDD v3.0 as we have miRNAs associated with it. 
In the end, we obtain a dataset with 5,390 disease-miRNA pairs, where half of them are positives and the 
other half are negatives. This dataset is balanced not only overall but also for each disease, and is used as 
independent test set, whose association pairs are not involved in model training. 
3 Graph Convolutional Networks 
GCN (Kipf and Welling, 2017) is trained in an end-to-end way and learns the informative node 
embedding for the semi-supervised classification tasks on a graph. The GCN is different from previous 
network embedding methods, e.g. node2vec (Grover and Leskovec, 2016), which needs firstly to learn 
node embedding from a graph, and then the learned embedding is fed into a supervised classifier for 
downstream classification tasks.  
Given a graph G and additional node feature vectors X: 
1. A node feature matrix X: a ܰ ൈ ܶ feature matrix, where N is the number of nodes in the graph G, and T is 
number of input features. In DimiG, for each node (gene), its expression values across 53 tissues from 
GTEx and the sum of its expression values across the 53 tissues are used as features, thus each node is 
represented as a 54-dimensional vector. 
2. An adjacency matrix A: a ܰ ൈ ܰ matrix, showing the connections between nodes in the graph G. If a PCG i 
interact with a miRNA or a PCG j, then the value A୧,୨ is 1, otherwise 0. 
3. The multi-hot encoded label matrix Y for some nodes but not all nodes in the graph, one node can have 
multiple labels. 
The GCN frames the classifying nodes in a graph as graph-based semi-supervised learning, where not 
all nodes in the graph need labels. To this end, a graph Laplacian regularization term is introduced into 
the loss function ܮ: 
ܮ ൌ 	ܮ଴ ൅ ߝ	 ∑ ܣ௜௝ฮ݂ሺ ௜ܺሻ െ 	݂൫ ௝ܺ൯ฮଶ௜௝  = ܮ଴ ൅ ߝ	݂ሺܺሻ்ሺܦ െ ܣሻ݂ሺܺሻ   (1) 
where ܮ଴is the supervised loss, f can be a neural network-based function, ߝ is the factor, X is the node 
features, A is the adjacency matrix and D is the degree matrix. 
A multi-layer GCN is propagated with the following rule: 
ܪ௟ାଵ ൌ 	݂൫ܪ௟, ܣ൯ ൌ 	ܴ݁ܮܷሺܣܪ௟ܹ௟ሻ                                    (2) 
where ܪ௟ is the output of layer l and ܹ௟ is a weight matrix. 
The GCN performs spectral convolutions on the graph and perform neighborhood weighting. A first-order 
approximation of localized spectral filters in Fourier-domain can be used to approximate the propagation 
rule (Defferrard  et al., 2016). Please refer to (Kipf and Welling, 2017) for more details on the GCN. 
For semi-supervised classification, we minimize the binary cross entropy loss on labeled data:  
ܮሺݓሻ ൌ 	െ∑ ݕ௜݈݋݃	ሺݕపෝሻே௜ୀଵ +(1-ݕ௜)log(1 െ	ݕపෝ ) + ߙ‖ݓ‖ଶଶ      (3) 
where y୧is	the	true	label	, yనෝ  is the output probability of the last sigmoid layer and α is the weight factor 
for regularization. 
4 Multi-label classification  
Multi-label classification assigns multiple labels to one node, and it is categorized into two groups: (1) 
problem transformation methods and (2) algorithm adaptation methods. For problem transformation 
methods, they are transformed into multiple binary classification problems, where each binary classifier is 
trained separately for each label. For algorithm adaptation methods, they usually perform multi-label 
classification directly using one classifier, which outputs predicted probabilities for all the labels.  
In DimiG’s multi-label assignment, we use the 2nd approach and set up a sigmoid layer as the last 
output layer, whose number of neurons is the number of labels. Given a set of labels with K classes (248 
diseases in this study), each node is assigned with several labels from it. Denote x as an input node, and y 
as a multi-hot encoded vector with 248 elements, which indicates absence of class i and presence of class 
i: y = [0, 1, 0, …, 1]. 
6 Baseline methods 
We formulate disease-miRNA association prediction as node classification in a graph, where nodes of 
PCGs are assigned multiple diseases as labels, and nodes of miRNAs are used as the test set. The 
miRNA-disease associations are completely not involved in model training of DimiG. To demonstrate the 
power of DimiG, we compare with two existing similar baseline methods that do not require disease 
information for miRNAs, and two variants of our DimiG model: 
1. miRPD:  it scores miRNA–disease associations by network analysis of miRNA–protein 
associations and protein–disease associations from text mining (Mork et al., 2014). We 
downloaded the inferred associations between diseases and miRNAs from their websites. In this 
study, we downloaded full dataset including croft_full.tsv.gz, miranda_full.tsv.gz and 
targetscan_full.tsv.gz. The three sets give the association scores between diseases and miRNAs, 
they are called miRBD-C, miRBD-M and miRBD-T, respectively. To make a fair comparison, 
we construct other two baseline methods miRBD-I-sum and miRBD-I-max, which use the same 
integrated miRNA-PCG associations from the RAIN database and disease-PCG associations from 
DISEASES database as DimiG. miRBD-I-sum and miRBD-I-max use sum and max to calculate 
the association scores between diseases and miRNAs, respectively. 
2. CNC: it is a co-expression-based method under guilt-by-association framework. For each disease 
d and miRNA, CNC consists of the following steps: 1) Calculate Pearson's correlation 
coefficients (PCC) between D-associated PCGs and the miRNA. 2) Keep only those co-
expression PCGs with absolute PCC > 0.3 and P-value < 0.01 (Liu and Zhao, 2016). 3) Calculate 
the mean value of up to K largest PCC value as the score for the miRNA with disease d. 
3. Two variant methods of DimiG: instead of using expression profiles across tissues as node 
features, we used one-hot encoding of all nodes. Simply, we use the identity matrix as the node 
feature matrix X. This variant method is called DimiG-I. In addition, we also construct another 
variant method DimiG-C, which combines the expression profiles and one-hot encoding as node 
features. 
     After obtaining the associated scores between diseases and miRNAs, we extracted scores for those 
positive and negative disease-miRNA pairs in the independent test set, and these scores are pooled 
together to calculate the area under the receiver operating characteristic curve (AUC) and the area under 
precision-recall curve (AUPRC). For miRPD, only those disease-miRNA pairs with scores in the 
download files are kept. 
    We also compare DimiG with other two state-of-the-art supervised methods BNPMDA (Chen et al., 2018) and 
DRMDA, both use miRNA-disease associations for model training. BNPMDA trains a bipartite network 
recommendation method on known disease-miRNA associations by integrating miRNA and disease similarity. 
DRMDA further uses stacked autoencoder to learn deep representation for diseases and miRNAs, which are fed into 
a support vector machine for predicting disease-miRNA associations. Both methods are trained on disease-miRNA 
associations from the database HMDD v2.0.  
    As mentioned above, cross-validation may yield biased performance. Thus, we evaluate how BNPMDA and 
DRMDA generalize to unseen miRNA-disease associations in the training set. We download the prediction 
association scores for available miRNAs and diseases from the supplementary material of these two studies, and the 
disease names are mapped to the disease ontology ID. Of the 1034 miRNAs and 248 diseases in this study, 304 
miRNAs and 55 diseases are in the score matrix predicted by BNPMDA and DRMDA. Instead, the DimiG does not 
use any disease-miRNA association information for model training, to make a fair and objective comparison, we 
evaluate the prediction performance of DimiG, BNPMDA and DRMDA on a dataset consisting of newly recorded 
verified miRNA-disease associations in HDMM v3.0 but not in HMDD v2.0. We call this dataset as an unseen 
disease-miRNA set, which is freely available at https://github.com/xypan1232/DimiG/tree/master/data. In this data 
set, there are 1954 disease-miRNA pairs consisting of 977 positives and 977 negatives, and it is also balanced not 
only overall but also for each disease. It should be noted that this data set may still have some possible dependent 
associations with the training set derived from HMDD v2.0. 
7 Experimental settings 
In this study, we modify the implemented GCN from https://github.com/tkipf/pygcn to support multi-
label classification using PyTorch framework. DimiG consists of two-layer GCNs. The last layer is the 
sigmoid layer with number of neurons 248, which is the number of diseases as labels. We use Adam to 
optimize the Binary Cross Entropy between the targets(Diederik and Jimmy, 2015). We use grid search to 
select the best parameters for learning rate, weight_decay and dropout probability. 
Of the 6,188 PCGs, we keep 80% of PCGs as the training set, 20% of PCGs as the validation set and all 
1034 miRNAs as the test set, which is used to evaluate the performance of DimiG for predicting disease-
associated miRNAs. For each PCG, the label is a 248-dimensional multi-hot vector indicating the 
presence of diseases associated with this PCG.  
8 Data construction for case studies 
In this study, we further evaluate the DimiG for predicting associated miRNAs for three types of diseases, 
i.e., prostate cancer, lung cancer and inflammatory bowel disease (IBD). For prostate cancer, of all the 
1034 miRNAs, 176 miRNAs are associated with prostate cancer in HMDD v3.0, which are used as the 
positives. For negative control, we randomly select other 176 miRNAs not associated with prostate cancer 
in the HMDD v3.0 as negatives. The 176 positives and 176 negatives comprise the prostate cancer 
specific dataset. Then we pool the predicted scores by DimiG of these total 352 miRNAs for prostate 
cancer and calculate the AUC scores for performance evaluation.  
We also use the same way to construct lung cancer and IBD specific datasets. Of the 1034 miRNAs, 
172 and 18 are recorded as association with lung cancer and IBD in HMDD v3.0 as positives, 
respectively. We also randomly selected the same number of miRNAs as negatives. For each of the three 
diseases, we will also check the overlap between the top 50 predicted miRNAs and its associated 
miRNAs in HMDD v3.0.  
In addition to the HMDD database, we also extract verified disease-miRNA associations from cancer 
database dbDEMC v2.0(Yang et al., 2017). We download disease-miRNA associations derived from low-
throughput methods. Of the 1034 miRNAs, 15 and 16 miRNAs are recorded as association with prostate 
cancer and lung cancer in dbDEMC v2.0, respectively. These two numbers are much fewer than that of 
HMDD v3.0, it is because only disease-miRNA associations verified by low-throughput methods before 
2017 are used for dbDEMC v2.0. Similarly, for each disease, we also randomly select the same number of 
miRNAs as negative controls. 
We also construct the disease-specific dataset from PhenomiR v2.0 (Ruepp et al., 2010) and miRCancer 
(version miRCancer18February2019) (Xie et al., 2013) for prostate cancer and lung cancer. We do the 
same data processing as the dbDEMC for the two databases, respectively. Of the 1034 miRNAs, 86 and 
60 miRNAs are associated with prostate cancer and lung cancer in miRCancer, respectively. We also 
select the same number of miRNAs not associated to prostate cancer and lung cancer in miRCancer as 
negative controls, respectively. For PhenomiR v2.0, we extract 157 and 190 miRNAs associated with 
prostate cancer and lung cancer, respectively. For each of the two cancers, the same number of miRNAs 
not associated with it in PhenomiR v2.0 is selected as negative samples. 
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Figure S1.The flowchart of data processing for constructing the benchmark set for DimiG. All 
the gene names are mapped to Ensembl gene IDs and disease names are mapped to Disease 
Ontology ID. Related to Figure 1 
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Figure S2. The number of disease distribution for  protein coding genes and miRNAs. A) PCGs; 
B) miRNAs. Related to Figure 1 
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Figure S4. Venn diagram and ROC curve of predicting associated miRNAs for prostate cancer, 
lung cancer using DimiG compared to verified disease-miRNA associations from miRCancer. A) 
and B), prostate cancer; C) and D), lung cancer. Related to Figure 5 
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 Figure S5. Venn diagram and ROC curve of predicting associated miRNAs for prostate cancer, 
lung cancer using DimiG compared to verified disease-miRNA associations from PhenomiR 2.0. 
A) and B), prostate cancer; C) and D), lung cancer. Related to Figure 5 
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